Check out articles in our own media – Binary District Journal. New Nordics!

 

 

Check out articles in our own media – Binary District Journal. New Nordics!

 

 

Home » What is Platform6? » Platform6 member Marginum raises €1.7 million in seed funding

Platform6 member Marginum raises €1.7 million in seed funding

Marginum joined Platform6 as a member in the summer of 2023, and their extraordinary startup journey and rapid growth have been truly impressive. We are very proud to have them in our community and look forward to further supporting their pursuit of new milestones and the realisation of their vision.

Marginum, founded in 2020, aims to improve the outcome and cost-effectiveness of cancer surgery with novel fluorescence-based optical tissue monitoring technology.  The company completed its seed funding round by raising private capital from Almaral, Nostetta Ventures, Redstone and a group of individual investors, coupled with Business Finland R&D loan.

Marginum’s solution empowers surgeons with fast and reliable information about tumour tissues. Accurate identification of tumours and distinguishing them from healthy tissues during cancer surgery is a critical challenge faced by surgeons globally. The company’s tissue monitoring technology aims to overcome surgical challenges that may lead to damaging healthy tissues and leaving tumour cells undetected. Incomplete tumour removal, damage to healthy tissues and reoperations all exacerbate patient suffering, long-term complications, and compromised standard of care – and directly escalating healthcare costs.

“Our tissue monitoring solution is the first-of-its-kind objective tumour detection platform. It integrates into current workflows and is unhindered by visual obstructions. The acquired seed funding enables us to finalise the development of our first product and positions the company well for market entry. This is a significant milestone”, says Marginum CEO Samu Lehtonen, medical doctor and engineer.

The €1.0 million private equity was coupled with a €0.7 million Business Finland R&D loan. The funding will be used for further service development and to enable high market penetration.

Nostetta Ventures participated with a follow-on investment. Among the investors in Marginum’s second funding round were two other reputable venture capital investors: Redstone and biotechnology‐focused Almaral.

“Almaral invests in early-stage biotech and life science companies with technologies that can significantly enhance healthcare professionals’ ability to deliver services with improved efficiency, quality, or significantly reduced costs, without compromising the quality of care. Marginum enables fundamental changes in the surgical market and contributes to solving a global health issue”, states Dr. Maria Severina, CEO of Almaral.

The €1.0 million private equity was coupled with a €0.7 million Business Finland R&D loan. The funding will be used for further service development and to enable high market penetration.

Read the full press release from their blog here: https://www.marginum.com/en/news/marginum-raises-1.7-million-for-market-entry-of-tissue-sensing-technology-for-cancer-surgery 

Read the article by Talouselämä herehttps://www.talouselama.fi/uutiset/suomalaisyhtio-voi-mullistaa-syopakirurgian-kerasi-miljoonarahoituksen/b02f400b-05ad-4b42-8079-792fd3be161f 

Åkerlundinkatu 8, 33100 Tampere